



Advances in Plasma Cell Dyscrasias

Guest Editors:

Dr. Despina Fotiou

Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece

Dr. Maria Gavriatopoulou

Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece

Dr. Ioannis Ntanasis-Stathopoulos

Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece

Deadline for manuscript submissions:

15 August 2024

Message from the Guest Editors

Plasma cell dyscrasias are a biologically and clinically heterogeneous group of diseases primarily characterized by the clonal expansion of plasma cells and monoclonal protein secretion. Significant research advances in the field during the past few years have led to improved outcomes for patients with multiple myeloma, AL amyloidosis and lymphoproliferative disorders. The ever-increasing understanding of the molecular mechanisms involved in disease pathogenesis and interactions in the tumor microenvironment have led to improved diagnostics, prognostication and novel agent development. Minimal residual disease assessment by NGF and NGS is being increasingly incorporated into clinical practice. Immunotherapy will probably be the next revolution in treatment for plasma cell malignancies. Patients with plasma cell leukemia, POEMs and other rare entities have also benefited from the development of new agents.

The goal of this Special Issue is to highlight important advances that have taken place in the diagnosis, management and treatment of plasma cell dyscrasias in recent years, and welcomes all papers that address aspects in these areas.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)